{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05710848",
            "orgStudyIdInfo": {
                "id": "STM-416-01"
            },
            "organization": {
                "fullName": "SURGE Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer",
            "officialTitle": "A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-stm-administered-to-patients-undergoing-turbt-for-recurrent-bladder-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-15",
            "studyFirstSubmitQcDate": "2023-01-25",
            "studyFirstPostDateStruct": {
                "date": "2023-02-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SURGE Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.",
            "detailedDescription": "This is a 2-part, multicenter, first-in-human (FIH), Phase 1/2a study in patients with a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary disease seen on cystoscopy, and who are undergoing TURBT without perioperative intravesical chemotherapy. All patients will receive relevant SOC therapy following TURBT. SOC will be administered in the adjuvant setting.\n\nPhase 1 is an open-label, single-treatment, dose-escalation study to evaluate the safety and tolerability of up to 4 increasing doses of intraoperatively administered STM-416 utilizing a 3+3 convention, with 3 to 6 patients enrolled in each STM-416 dose level, with a minimum of 6 patients enrolled at the highest dose level, for a total of approximately 24 patients.\n\nPhase 2a is a randomized, single-blind, single-treatment, dose-expansion study that will comprise 2 arms: TURBT + STM-416 Dose 1 followed by SOC versus TURBT + STM-416 Dose 2 followed by SOC."
        },
        "conditionsModule": {
            "conditions": [
                "Non-muscle-invasive Bladder Cancer"
            ],
            "keywords": [
                "Open-label",
                "Dose escalation",
                "STM-416",
                "Resiquimod",
                "Toll-like receptor 7/8",
                "Non-Muscle Invasive Bladder Cancer",
                "TURBT",
                "Immunotherapy",
                "BCG"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Singe group assignment",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 75,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "STM-416",
                    "type": "EXPERIMENTAL",
                    "description": "STM-416",
                    "interventionNames": [
                        "Drug: STM-416"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "STM-416",
                    "description": "STM-416 monotherapy",
                    "armGroupLabels": [
                        "STM-416"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability] Phase 1",
                    "description": "Incidence of dose-limiting toxicities (DLTs) over the first 21-days of study treatment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Phase 1",
                    "description": "Incidence of serious adverse events (SAEs), and adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0",
                    "timeFrame": "Time on trial up to 90 days"
                },
                {
                    "measure": "Recurrence free survival time (Phase 2a)",
                    "description": "Recurrence will be evaluated by cystoscopy and urine cytology",
                    "timeFrame": "Through study completion up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics of STM-416 (Phase 1)",
                    "description": "Maximum plasma concentration (Cmax) of resiquimod (R848) in patient blood for the single dose level (Phase 1)",
                    "timeFrame": "Day 0, post 24 hours, post 48 hour"
                },
                {
                    "measure": "Pharmacokinetics of STM-416 (Phase 1)",
                    "description": "Area under the plasma concentration versus time curve (AUC) of resiquimod (R848) in patient blood for the single dose level (Phase 1)",
                    "timeFrame": "Day 0, post 24 hours, post 24 hour"
                },
                {
                    "measure": "Pharmacodynamics of STM-416",
                    "description": "Pharmacodynamic assessments in plasma and urine will be listed and summarized by dose level for Phase 1/2a",
                    "timeFrame": "Day 0, post 24 hours, post 48 hours, post 21 days, post 90 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Are aged 18 years or older;\n2. Have a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary disease seen on cystoscopy, and who are undergoing TURBT without perioperative intravesical chemotherapy;\n3. Are considered high risk for recurrence;\n4. Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;\n5. Have adequate organ and marrow function as defined below:\n\n   * Hemoglobin 9.0 g/dL;\n   * Absolute neutrophil count 1.5 \u00d7 109/L (1500 per mm3);\n   * Platelet count 75 \u00d7 109/L (75,000 per mm3);\n   * Serum bilirubin 1.5 \u00d7 institutional upper limit of normal (ULN);\n   * AST (serum glutamic-oxaloacetic transaminase)/ALT (serum glutamic-pyruvic transaminase) 2.5 \u00d7 institutional ULN; and\n   * Creatinine CL 60 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine CL: Males: Creatinine CL (mL/min) = Weight (kg) \u00d7 (140 - Age)/72 \u00d7 serum creatinine (mg/dL); or Females: Creatinine CL (mL/min) = Weight (kg) \u00d7 (140 - Age) \u00d7 0.85/72 \u00d7 serum creatinine (mg/dL).\n\nExclusion Criteria:\n\n1. Have a history of CIS or MIBC;\n2. Are receiving any other investigational agents;\n3. Have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to resiquimod (R848), or excipients used in STM-416 including poloxamer 407 and sodium hyaluronate;\n4. Have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n\n   Urinary tract infections are not exclusionary unless they are NCI-CTCAE Grade 3 or higher;\n5. Are a woman of childbearing potential regardless of contraceptive use; Note: Women of childbearing potential are only to be excluded in Phase 1 and Phase 2a to avoid bias due to the low prevalence of NMIBC in this population. However, they will be included in subsequent Phase 2/3 studies.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "genderBased": true,
            "genderDescription": "Women of childbearing potential are only to be excluded in Phase 1 and Phase 2a to avoid bias due to the low prevalence of NMIBC in this population.",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kayti Aviano",
                    "role": "CONTACT",
                    "phone": "781-605-8632",
                    "email": "kayti@surgetx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Seth Lerner, MD",
                    "affiliation": "Baylor College of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Arizona Urology Specialists",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85715",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christina Montijo",
                            "role": "CONTACT",
                            "email": "cmontijo@arizonauro.com"
                        },
                        {
                            "name": "Susan Kalota, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "University of Florida",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32608",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Casey Walsh",
                            "role": "CONTACT",
                            "email": "CaseyWalsh@cancer.ufl.edu"
                        },
                        {
                            "name": "Padraic O'Malley, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "Beth Israel Deaconess Medical Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Boris Gershman, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Duke Cancer Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shawna Pochan",
                            "role": "CONTACT",
                            "email": "shawna.pochan@duke.edu;"
                        },
                        {
                            "name": "Michael Abern, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "The Ohio State University",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43221",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kendall Lewis",
                            "role": "CONTACT",
                            "email": "Kendall.Lewis@osumc.edu"
                        },
                        {
                            "name": "Kamal Pohar, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jessica Richardson",
                            "role": "CONTACT",
                            "email": "Jrichardson@curcmb.com"
                        },
                        {
                            "name": "Abhishek Srivastava, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Urology Associates, P.C.",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37209",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joe Wallace",
                            "role": "CONTACT",
                            "email": "jawallace@ua-pc.com"
                        },
                        {
                            "name": "Gautam Jayram, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jose Santoyo",
                            "role": "CONTACT",
                            "email": "Jose.Santoyo@UTSouthwestern.edu"
                        },
                        {
                            "name": "Yair Lotan, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Baylor College of Medicine",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharon Harrison",
                            "role": "CONTACT",
                            "email": "sharons@bcm.edu"
                        },
                        {
                            "name": "Seth Paul Lerner, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Houston Methodist",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Taliah Muhammad",
                            "role": "CONTACT",
                            "email": "tnmuhammad@houstonmethodist.org"
                        },
                        {
                            "name": "Raj Satkunasivam, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                },
                {
                    "id": "D000093284",
                    "term": "Non-Muscle Invasive Bladder Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M2976",
                    "name": "Non-Muscle Invasive Bladder Neoplasms",
                    "asFound": "Non-muscle Invasive Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4793",
                    "name": "BCG Vaccine",
                    "relevance": "LOW"
                },
                {
                    "id": "M354039",
                    "name": "Resiquimod",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}